Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.75 AUD | 0.00% | -1.69% | -9.09% |
03-19 | Cyclopharm's Technegas Device Carries Out Imaging of First US Patients | MT |
03-18 | Cyclopharm Limited(ASX:CYC) added to S&P/ASX All Ordinaries Index | CI |
Sales 2024 * | 37.4M 24.43M 33.37M | Sales 2025 * | 60.9M 39.78M 54.33M | Capitalization | 165M 108M 147M |
---|---|---|---|---|---|
Net income 2024 * | -2M -1.31M -1.78M | Net income 2025 * | 11M 7.19M 9.81M | EV / Sales 2024 * | 4.41 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 2.71 x |
P/E ratio 2024 * |
-69.7
x | P/E ratio 2025 * |
14.3
x | Employees | 87 |
Yield 2024 * |
0.57% | Yield 2025 * |
3.5% | Free-Float | 45.15% |
1 week | -1.69% | ||
Current month | -2.51% | ||
1 month | -4.63% | ||
3 months | -5.41% | ||
6 months | -13.79% | ||
Current year | -9.09% |
Managers | Title | Age | Since |
---|---|---|---|
James McBrayer
CEO | Chief Executive Officer | 58 | 08-06-02 |
Mathew Farag
COO | Chief Operating Officer | - | 16-12-31 |
Mark Doverty
PRN | Corporate Officer/Principal | - | 19-09-29 |
Members of the board | Title | Age | Since |
---|---|---|---|
Dianne Angus
BRD | Director/Board Member | 63 | 21-08-09 |
James McBrayer
CEO | Chief Executive Officer | 58 | 08-06-02 |
David Heaney
CHM | Chairman | 79 | 06-11-19 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 1.75 | 0.00% | 220 |
24-04-24 | 1.75 | -1.69% | 18,513 |
24-04-22 | 1.78 | 0.00% | 12,000 |
24-04-19 | 1.78 | 0.00% | 14,941 |
Delayed Quote Australian S.E., April 25, 2024 at 08:02 pm
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-9.09% | 107M | |
+8.07% | 219B | |
+6.59% | 183B | |
+11.26% | 133B | |
+26.57% | 108B | |
+0.65% | 63.06B | |
+13.35% | 52.02B | |
-0.62% | 48.2B | |
-0.93% | 40.37B | |
+11.54% | 39.35B |
- Stock Market
- Equities
- CYC Stock